Investigator Site 0010095
Investigator Site 0010095
Oklahoma City, Oklahoma, United States1 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 3 | 2026-09-23 | NCT04812925 |